Low dose of mycophenolate mofetil is enough in desensitized kidney transplantation using rituximabReportar como inadecuado

Low dose of mycophenolate mofetil is enough in desensitized kidney transplantation using rituximab - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

BMC Nephrology

, 16:201

Dialysis and Transplantation


BackgroundRituximab is widely used in kidney transplantation. However, it is not clear whether the conventional doses of maintenance immunosuppressant in rituximab-treated kidney transplantation KT are appropriate. In our previous study, decreasing mycophenolate mofetil MMF dose due to infection did not increase the incidence of rejection or graft failure. Based on these experiences, we developed a new protocol with a lower dose of MMF and studied its clinical outcomes in rituximab-treated KT.

MethodsWe enrolled all patients who underwent ABO-incompatible or human leukocyte antigen HLA-sensitized living donor KT with the new immunosuppressant protocol after preconditioning with rituximab, but without splenectomy from November 2011 to May 2013. Seventy-two patients group 1 were consecutively enrolled in this study and followed until November 2013. Patients from our previous study served as control groups. Sixty-seven patients received KT using rituximab with a conventional dose of MMF group 2, and 87 patients received ABO compatible KT without need for rituximab group 3. Clinical outcomes, including rejection, infection, and graft survival, were compared between the groups. The χ test and Fisher’s exact test were used for categorical variables, the Student’s t-test and Mann-Whitney U test were used for continuous variables, and a log-rank test was used for mortality analysis.

ResultsDoses of postoperative MMF g-day were lower in group 1 than in the other groups 1.03 ± 0.19, 1.48 ± 0.34 and 1.48 ± 0.32 g-day at 1 week, p < 0.001. Infectious complications occurred more often in groups with conventional MMF doses group 2 and 3 than in group 1 16.7 vs. 37.3 %, p = 0.007 and 16.7 vs. 34.5 %, p = 0.012, respectively. Notably, group 1 showed a lower incidence of cytomegalovirus infection than group 2. However, reduction in MMF dose did not increase the incidence of acute rejection 4.2, 4.5 and 10.3 %. Only one graft failure occurred in group 2 due to vessel kinking after operation. There were no significant differences in the incidence of malignancy and mortality between groups.

ConclusionsA low MMF dose reduces infection without increasing rejection or graft loss and it may be appropriate to reduce the dose of MMF for rituximab-treated KT patients.

KeywordsRituximab Kidney transplantation Immunosuppression AbbreviationsABOiABO incompatible


HLAHuman leukocyte antigen

KTKidney transplantation

MMFMycophenolate mofetil

Download fulltext PDF

Autor: Chung Hee Baek - Hyosang Kim - Hoon Yu - Eunhye Shin - Hyungjin Cho - Won Seok Yang - Duck Jong Han - Su-Kil Park

Fuente: https://link.springer.com/

Documentos relacionados